Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company, announced a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 12:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company, announced a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 12:00 PM ET. The event aims to discuss the company’s innovative approaches in developing therapeutics for immune-mediated diseases.
The company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody targeting TL1A, showing promise for conditions like ulcerative colitis and Crohn’s Disease. A live and archived webcast will be available on the Prometheus Biosciences investor page.
Details
News Market Reaction – RXDX
The recorded move for RXDX in the trading session of this news was +4.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET.
A live and archived webcast of the fireside chat will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases. The Company’s target discovery engine, Prometheus360™, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.
The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity and has the potential to substantially improve outcomes for moderate-to-severe IBD patients predisposed to increased TL1A expression. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis (UC), Crohn’s Disease (CD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Prometheus Biosciences Contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com
Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.